Infections Are Leading Cause of Hospital Death in Indian Patients with Inflammatory Myopathy
vitalworks / Pixabay

Infections Are Leading Cause of Hospital Death in Indian Patients with Inflammatory Myopathy

  According to a recent article, researchers investigated the cause of deaths in the hospital in patients who were diagnosed with inflammatory myositis in a tertiary care center in Northern…

Continue Reading Infections Are Leading Cause of Hospital Death in Indian Patients with Inflammatory Myopathy
ACR Convergence 2020: Data Available on Octagam 10% for Dermatomyositis
https://pixabay.com/photos/hospital-infusion-hand-association-834157/

ACR Convergence 2020: Data Available on Octagam 10% for Dermatomyositis

  This year, the American College of Rheumatology (ACR) held their Convergence 2020 meeting virtually from November 5-9, with additional poster presentations on November 10 and 21. According to a…

Continue Reading ACR Convergence 2020: Data Available on Octagam 10% for Dermatomyositis
Experimental Drug Earns Orphan Drug Designation for Polymyositis and Dermatomyositis
source: pixabay.com

Experimental Drug Earns Orphan Drug Designation for Polymyositis and Dermatomyositis

According to a story from Biotech 365, the biotechology company Kezar Life Sciences, Inc. recently announced that its experimental therapy KZR-616 has earned Orphan Drug designations from the US Food…

Continue Reading Experimental Drug Earns Orphan Drug Designation for Polymyositis and Dermatomyositis
Safe Pregnancies with Rheumatic Diseases are Possible with Planning
source: pixabay.com

Safe Pregnancies with Rheumatic Diseases are Possible with Planning

Dr. Lisa Sammaritano from Weill Cornell Medical College has explained a way to lower risks within pregnancy for those with rheumatic diseases. Pregnancy and Rheumatic Diseases Patients who have a…

Continue Reading Safe Pregnancies with Rheumatic Diseases are Possible with Planning
Researchers Find Effective Biomarker for Predicting Severity of Myositis-Associated Interstitial Lung Disease
source: pixabay.com

Researchers Find Effective Biomarker for Predicting Severity of Myositis-Associated Interstitial Lung Disease

A team of researchers recently evaluated a new biomarker in interstitial lung disease to see whether or not it could predict disease severity and ultimately mortality. The Biomarker Surfactant protein…

Continue Reading Researchers Find Effective Biomarker for Predicting Severity of Myositis-Associated Interstitial Lung Disease
The Importance of Cancer Screenings in Patients with Scleroderma, Dermatomyositis
Elizabeth M. Dugan, Adam M. Huber, Frederick W. Miller, Lisa G. Rider / CC BY-SA (https://creativecommons.org/licenses/by-sa/3.0)

The Importance of Cancer Screenings in Patients with Scleroderma, Dermatomyositis

  This year, because of COVID-19, many healthcare-related events and symposiums have been moved online. However, that doesn't mean that the insights are any less helpful! In the virtual ACR…

Continue Reading The Importance of Cancer Screenings in Patients with Scleroderma, Dermatomyositis

Hydroxychloroquine Shortage: What About Patients with Autoimmune Disorders?

According to CNBC, there is a shortage across the country of a very important medication: hydroxychloroquine. This is somewhat unsurprising. After all, the Trump administration has been vocal about the…

Continue Reading Hydroxychloroquine Shortage: What About Patients with Autoimmune Disorders?
Updates on Studies Investigating Lenabasum as a Potential Treatment for Systemic Sclerosis and Dermatomyositis
stevepb / Pixabay

Updates on Studies Investigating Lenabasum as a Potential Treatment for Systemic Sclerosis and Dermatomyositis

New data has been released about the effects of lenabasum, an experimental drug, on patients with systemic sclerosis and dermatomyositis. Corbus, who are developing lenabasum, are planning to present the…

Continue Reading Updates on Studies Investigating Lenabasum as a Potential Treatment for Systemic Sclerosis and Dermatomyositis
The FDA Have Awarded Orphan Drug Designation to an Experimental Treatment for Dermatomyositis
Aymanjed / Pixabay

The FDA Have Awarded Orphan Drug Designation to an Experimental Treatment for Dermatomyositis

The US Food and Drug Administration has awarded Orphan Drug Designation to the drug lenabasum as a treatment for dermatomyositis. The use of lenabasum for treating this condition, and others,…

Continue Reading The FDA Have Awarded Orphan Drug Designation to an Experimental Treatment for Dermatomyositis

Experimental Treatment for Dermatomyositis Fails to Meet Endpoints in Phase 2 Trial

According to a story from globenewswire.com, the biopharmaceutical company Idera Pharmaceuticals recently released the data from its Phase 2 trial for IMO-8400, an investigational product in development for the treatment…

Continue Reading Experimental Treatment for Dermatomyositis Fails to Meet Endpoints in Phase 2 Trial